CD274 and neoplasm: Atezolizumab is a humanized monoclonal anti‐programmed death ligand 1 (PD‐L1) antibody, an immune checkpoint inhibitor that blocks PD‐L1‐programmed death 1 (PD‐1) and PD‐L1‐B7‐1 signaling and recovers tumor‐specific T‐cell immunity.18